These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
374 related articles for article (PubMed ID: 24121499)
1. Apolipoproteins C-I and C-III inhibit lipoprotein lipase activity by displacement of the enzyme from lipid droplets. Larsson M; Vorrsjö E; Talmud P; Lookene A; Olivecrona G J Biol Chem; 2013 Nov; 288(47):33997-34008. PubMed ID: 24121499 [TBL] [Abstract][Full Text] [Related]
2. Effects of plasma apolipoproteins on lipoprotein lipase-mediated lipolysis of small and large lipid emulsions. Yamamoto M; Morita SY; Kumon M; Kawabe M; Nishitsuji K; Saito H; Vertut-Doï A; Nakano M; Handa T Biochim Biophys Acta; 2003 Jun; 1632(1-3):31-9. PubMed ID: 12782148 [TBL] [Abstract][Full Text] [Related]
4. Very low-density lipoprotein/lipo-viro particles reverse lipoprotein lipase-mediated inhibition of hepatitis C virus infection via apolipoprotein C-III. Sun HY; Lin CC; Lee JC; Wang SW; Cheng PN; Wu IC; Chang TT; Lai MD; Shieh DB; Young KC Gut; 2013 Aug; 62(8):1193-203. PubMed ID: 22689516 [TBL] [Abstract][Full Text] [Related]
5. Identification of a lipoprotein lipase cofactor-binding site by chemical cross-linking and transfer of apolipoprotein C-II-responsive lipolysis from lipoprotein lipase to hepatic lipase. McIlhargey TL; Yang Y; Wong H; Hill JS J Biol Chem; 2003 Jun; 278(25):23027-35. PubMed ID: 12682050 [TBL] [Abstract][Full Text] [Related]
6. Apolipoprotein C-III inhibits triglyceride hydrolysis by GPIHBP1-bound LPL. Larsson M; Allan CM; Jung RS; Heizer PJ; Beigneux AP; Young SG; Fong LG J Lipid Res; 2017 Sep; 58(9):1893-1902. PubMed ID: 28694296 [TBL] [Abstract][Full Text] [Related]
7. Abnormal activation of lipoprotein lipase by non-equilibrating apoC-II: further evidence for the presence of non-equilibrating pools of apolipoproteins C-II and C-III in plasma lipoproteins. Tornoci L; Scheraldi CA; Li X; Ide H; Goldberg IJ; Le NA J Lipid Res; 1993 Oct; 34(10):1793-803. PubMed ID: 8245727 [TBL] [Abstract][Full Text] [Related]
8. Human apolipoprotein A-II determines plasma triglycerides by regulating lipoprotein lipase activity and high-density lipoprotein proteome. Julve J; Escolà-Gil JC; Rotllan N; Fiévet C; Vallez E; de la Torre C; Ribas V; Sloan JH; Blanco-Vaca F Arterioscler Thromb Vasc Biol; 2010 Feb; 30(2):232-8. PubMed ID: 19910634 [TBL] [Abstract][Full Text] [Related]
9. Effects of sphingomyelin and cholesterol on lipoprotein lipase-mediated lipolysis in lipid emulsions. Arimoto I; Saito H; Kawashima Y; Miyajima K; Handa T J Lipid Res; 1998 Jan; 39(1):143-51. PubMed ID: 9469593 [TBL] [Abstract][Full Text] [Related]
10. Characterization of recombinant wild type and site-directed mutations of apolipoprotein C-III: lipid binding, displacement of ApoE, and inhibition of lipoprotein lipase. Liu H; Talmud PJ; Lins L; Brasseur R; Olivecrona G; Peelman F; Vandekerckhove J; Rosseneu M; Labeur C Biochemistry; 2000 Aug; 39(31):9201-12. PubMed ID: 10924113 [TBL] [Abstract][Full Text] [Related]
11. Apolipoprotein E effectively inhibits lipoprotein lipase-mediated lipolysis of chylomicron-like triglyceride-rich lipid emulsions in vitro and in vivo. Rensen PC; van Berkel TJ J Biol Chem; 1996 Jun; 271(25):14791-9. PubMed ID: 8662966 [TBL] [Abstract][Full Text] [Related]
12. The angiopoietin-like proteins ANGPTL3 and ANGPTL4 inhibit lipoprotein lipase activity through distinct mechanisms. Shan L; Yu XC; Liu Z; Hu Y; Sturgis LT; Miranda ML; Liu Q J Biol Chem; 2009 Jan; 284(3):1419-24. PubMed ID: 19028676 [TBL] [Abstract][Full Text] [Related]
13. Lipoprotein lipase-catalyzed hydrolysis of phosphatidylcholine of guinea pig very low density lipoproteins and discoidal complexes of phospholipid and apolipoprotein: effect of apolipoprotein C-II on the catalytic mechanism. Shirai K; Fitzharris TJ; Shinomiya M; Muntz HG; Harmony JA; Jackson RL; Quinn DM J Lipid Res; 1983 Jun; 24(6):721-30. PubMed ID: 6688442 [TBL] [Abstract][Full Text] [Related]
14. Angiopoietin-like 4 Modifies the Interactions between Lipoprotein Lipase and Its Endothelial Cell Transporter GPIHBP1. Chi X; Shetty SK; Shows HW; Hjelmaas AJ; Malcolm EK; Davies BS J Biol Chem; 2015 May; 290(19):11865-77. PubMed ID: 25809481 [TBL] [Abstract][Full Text] [Related]
15. Influence of lipoprotein lipase and hepatic lipase on the transformation of VLDL and HDL during lipolysis of VLDL. Murdoch SJ; Breckenridge WC Atherosclerosis; 1995 Dec; 118(2):193-212. PubMed ID: 8770314 [TBL] [Abstract][Full Text] [Related]
16. Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD. Taskinen MR; Packard CJ; Borén J Curr Atheroscler Rep; 2019 May; 21(8):27. PubMed ID: 31111320 [TBL] [Abstract][Full Text] [Related]
18. ApoC-III ASO promotes tissue LPL activity in the absence of apoE-mediated TRL clearance. Ramms B; Patel S; Nora C; Pessentheiner AR; Chang MW; Green CR; Golden GJ; Secrest P; Krauss RM; Metallo CM; Benner C; Alexander VJ; Witztum JL; Tsimikas S; Esko JD; Gordts PLSM J Lipid Res; 2019 Aug; 60(8):1379-1395. PubMed ID: 31092690 [TBL] [Abstract][Full Text] [Related]
19. A Pressure-dependent Model for the Regulation of Lipoprotein Lipase by Apolipoprotein C-II. Meyers NL; Larsson M; Olivecrona G; Small DM J Biol Chem; 2015 Jul; 290(29):18029-18044. PubMed ID: 26026161 [TBL] [Abstract][Full Text] [Related]
20. Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III. Wang CS; McConathy WJ; Kloer HU; Alaupovic P J Clin Invest; 1985 Feb; 75(2):384-90. PubMed ID: 3973011 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]